

Lenvatinib

Chemical Properties

CAS No. : 417716-92-8

Formula: C₂₁H₁₉ClN₄O₄


Molecular Weight: 426.85

Storage:

Store at low temperature, The compound is unstable in solution. Please use soon

Powder: -20°C for 3 years

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC ₅₀ =4/5.2 nM). Lenvatinib has strong anti-tumor activity.
Targets(IC ₅₀)	FGFR,c-RET,c-Kit,PDGFR,VEGFR
In vitro	<p>METHODS: Six human tumor cells, A375, DU145, DX3, KM12C, SK23, and U2OS, were treated with Lenvatinib (1-100 μM) for 72 h. Cell viability was measured by MTT.</p> <p>RESULTS: In most cell lines, Lenvatinib inhibited proliferation only at high concentrations (IC₅₀ 23.6-44.17 μM), while the IC₅₀ in the KM12C cell line was 9.54 μM. [1]</p> <p>METHODS: Human umbilical vein endothelial cells HUVECs were treated with Lenvatinib (0.16-20 nM) for 1 h, followed by stimulation with SCF or VEGF (20 ng/mL) for 5 min, and the expression levels of target proteins were detected by Western Blot.</p> <p>RESULTS: Ligand-induced phosphorylation of both KIT and KDR was inhibited by Lenvatinib. [2]</p>
In vivo	<p>METHODS: To assay antitumor activity in vivo, Lenvatinib (30-100 mg/kg in 0.5% methylcellulose) was orally administered twice daily for twenty-one days to BALB/c nude mice harboring human small cell lung cancer tumor H146.</p> <p>RESULTS: Oral administration of Lenvatinib inhibited the growth of H146 tumors in a dose-dependent manner and caused tumor regression at 100 mg/kg. [2]</p> <p>METHODS: To test the antitumor activity in vivo, Lenvatinib (100 mg/kg) was orally administered once daily for eight weeks to nude mice harboring human mammary carcinoma tumor MDA-MB-231.</p> <p>RESULTS: Lenvatinib inhibited metastasis to regional lymph nodes and distant lungs in the MDA-MB-231 xenograft model. Lenvatinib decreased angiogenesis and lymphangiogenesis in established metastatic nodes of MDA-MB-231 tumors in lymph nodes. [3]</p>
Kinase Assay	In vitro kinase assay [1]: Tyrosine kinase assays are performed by HTRF (KDR, VEGFR1, FGFR1, c-Met, EGFR) and ELISA (PDGFRβ), using the recombinant kinase domains of receptors. In both assays, 4 μL of serial dilutions of E7080 are mixed in a 96-well round plate with 10 μL of enzyme, 16 μL of poly (GT) solution (250 ng) and 10 μL of ATP

Kinase Assay	solution (1 μ M ATP) (final concentration of DMSO is 0.1%). In wells for blanks, no enzyme is added. In control wells no test article is added. The kinase reaction is initiated by adding ATP solution to each well. After 30-minute incubation at 30°C, the reaction is stopped by adding 0.5 M EDTA (10 μ L/well) to the reaction mixture in each well. Dilution buffer adequate to each kinase assay is added to the reaction mixture. In the HTRF assay, 50 μ L of the reaction mixture is transferred to a 96-well 1/2 area black EIA/RIA plate, HTRF solution (50 μ L/well) is added to the reaction mixture, and then kinase activity is determined by measurement of fluorescence with a time-resolved fluorescence detector at an excitation wavelength of 337 nm and an emission wavelengths of 620 and 665 nm. In the ELISA, 50 μ L of the reaction mixture is incubated in avidin coated 96-well polystyrene plates at room temperature for 30 minutes. After washing with wash buffer, PY20-HRP solution (70 μ L/well) is added and the reaction mixture is incubated at room temperature for 30 minutes. After washing with wash buffer, TMB reagent (100 μ L/well) is added to each well. After several minutes (10–30 minutes), 1 M H ₃ PO ₄ (100 μ L/well) is added to each well. Kinase activity is determined by measurement of absorbance at 450 nm with a microplate reader.
Cell Research	HUVECs (1,000 cells in each well in serum-free medium containing 2% fetal bovine serum) and L6 rat skeletal muscle myoblasts (5,000 cells in each well in serum-free DMEM) are dispensed in a 96-well plate and incubated overnight. E7080 and either VEGF (20 ng/mL) or FGF-2 (20 ng/mL) containing 2% fetal bovine serum and PDGF β (40 ng/mL) are added to each well. Cells are incubated for 3 days and then the ratios of surviving cells are measured by WST-1 reagent. For proliferation assay, samples are duplicated and three separate experiments are done. (Only for Reference)

Solubility Information

Solubility	DMSO: 22.22 mg/mL (52.06 mM),Sonication is recommended. The compound is unstable in solution. Please use soon. Ethanol: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.9 mg/mL (4.45 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3427 mL	11.7137 mL	23.4274 mL
5 mM	0.4685 mL	2.3427 mL	4.6855 mL
10 mM	0.2343 mL	1.1714 mL	2.3427 mL
50 mM	0.0469 mL	0.2343 mL	0.4685 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Glen H, et al. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. *BMC Cancer*. 2011 Jul 22;11:309.
- Kui L, Kong Q, Yang X, et al. High-throughput in vitro gene expression profile to screen of natural herbals for Breast Cancer treatment. *Frontiers in Oncology*. 2021, 11.
- Sun L, Wan A H, Yan S, et al. A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance. *Acta Pharmaceutica Sinica B*. 2023
- Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. *Int J Cancer*. 2008 Feb 1;122(3):664-71.
- Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. *Clin Cancer Res*. 2008 Sep 1;14(17):5459-65.
- Cao M M, Li Y M, Ding X, et al. ARL8B promotes hepatocellular carcinoma progression and inhibits antitumor activity of lenvatinib via MAPK/ERK signaling by interacting with RAB2A. *Cellular Signalling*. 2024: 111470.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481